NCT01080131 · MORE INFO

Limitations, agreements, and source contact

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study. · Source last updated 2014-01-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

other Details: The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

organization: Novartis Pharmaceuticals
phone: 862 778-8300
title: Study Director

Complete source fields

certain Agreement

other Details: The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

organization: Novartis Pharmaceuticals
phone: 862 778-8300
title: Study Director

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice